Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis
β Scribed by Elisabetta Bugianesi; Gulio Marchesini; Elena Gentilcore; Ian Homer Y. Cua; Ester Vanni; Mario Rizzetto; Jacob George
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 229 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead to hepatic fibrosis and cirrhosis. Portal fibrosis in the absence of NASH, called isolated portal fibrosis (IPF), has received less attention and has not been classified as a spectrum
Children and adolescents with normal ALT levels differed significantly from those with abnormal aminotransferases in waist circumference (P Ο 0.05), triglycerides (P Ο 0.05), 2-hour glucose (P Ο 0.004), and insulin (P Ο 0.01) after a standard load of 75 g glucose. On univariate analysis, in the grou
It is uncertain whether patients with nonalcoholic fatty liver disease (NAFLD) and normal alanine aminotransferase (ALT) have a milder disease and should undergo liver biopsy. We reviewed the histological data of 458 Italian patients with NAFLD in whom liver biopsy was indicated by altered liver enz
Only 20% of patients with chronic hepatitis C (CHC) will develop cirrhosis, and fibrosis progression remains highly unpredictable. A recent genome-wide association study identified a genetic variant in the patatin-like phospholipase-3 (PNPLA3) gene (rs738409 C>G) associated with steatosis that was f